{"id":475613,"date":"2021-04-13T09:04:05","date_gmt":"2021-04-13T13:04:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/"},"modified":"2021-04-13T09:04:05","modified_gmt":"2021-04-13T13:04:05","slug":"therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/","title":{"rendered":"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Company Announces Second Therapeutic Candidate for Leveraging Regenerative and Immunological Approaches for Overcoming &gt; $78.5 Billion Dollar Addiction Epidemic<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">ELK CITY, Idaho<\/span>, <span class=\"xn-chron\">April 13, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced filing of a patent with new data covering a cord blood based intranasal product demonstrated to reduce adverse mental effects associated with opioid addiction.\u00a0 <\/p>\n<p>In the series of studies, inflammation was stimulated in the brains of animals using inducers and activators of TLR4, a protein associated with opioid addiction.\u00a0 Administration of the Company&#8217;s cord blood based therapeutic resulted in suppression of TLR4 as well as inhibition of inflammation in the brain. <\/p>\n<p>&#8220;In recent times numerous publications have reported the link between brain inflammation and opioid addiction<sup>1<\/sup>,<sup>2<\/sup>&#8221; said Dr. <span class=\"xn-person\">James Veltmeyer<\/span>, Chief Medical Officer of Campbell Neurosciences. &#8220;By combining the regenerative effects of umbilical cord blood, with the anti-inflammatory properties of NanoStilbene\u00e4, together with proprietary neuromodulating agents, we have created a treatment approach which appears to be safe and potently effective in our preclinical studies.&#8221;<\/p>\n<p>&#8220;Campbell Neurosciences is focused not just on identifying suicidal ideations utilizing our clinically validated Campbell Score\u2122 blood-based test, but also on providing possible solutions to prevent suicide,&#8221; said <span class=\"xn-person\">Kalina O&#8217;Connor<\/span>, President and CEO of Campbell Neurosciences. &#8220;The announcement of preclinical success using our cord blood based approach sets the foundation for optimization and development of a clinically-useful approach to treat this dreaded disease.&#8221;<\/p>\n<p>&#8220;Current approaches to drug addiction many times involve replacing one addiction with another one, while not addressing the root cause,&#8221; said <span class=\"xn-person\">Timothy Dixon<\/span>, President and CEO of Therapeutic Solutions International, the Parent Company of Campbell Neurosciences and co-inventor of the patent. &#8220;We are glad to lend our immunological expertise to Campbell Neurosciences for the development of the world&#8217;s first immunotherapeutic approach to opioid addiction.&#8221;\u00a0 <\/p>\n<p>\n        <b>About Therapeutic Solutions International, Inc.<br \/><\/b>Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company&#8217;s corporate website is <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3127149-1&amp;h=1861221295&amp;u=http%3A%2F%2Fwww.therapeuticsolutionsint.com%2F&amp;a=www.therapeuticsolutionsint.com\" rel=\"nofollow noopener\">www.therapeuticsolutionsint.com<\/a>, and our public forum is <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3127149-1&amp;h=2009033132&amp;u=https%3A%2F%2Fboard.therapeuticsolutionsint.com%2F&amp;a=https%3A%2F%2Fboard.therapeuticsolutionsint.com%2F\" rel=\"nofollow noopener\">https:\/\/board.therapeuticsolutionsint.com\/<\/a><b>\u00a0<\/b><\/p>\n<p>\n        <a target=\"_blank\" href=\"mailto:ir@tsoimail.com\" rel=\"nofollow noopener\">ir@tsoimail.com<\/a>\n      <\/p>\n<p>1 Eidson et al. Inflammatory mediators of opioid tolerance: Implications for dependency and addiction. Peptides. 2019 May;115:51-58.<br \/>2 Hofford et al. Neuroimmune mechanisms of psychostimulant and opioid use disorders. Eur J Neurosci. 2019 Aug;50(3):2562-2573.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA40663&amp;sd=2021-04-13\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction-301267713.html\">http:\/\/www.prnewswire.com\/news-releases\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction-301267713.html<\/a><\/p>\n<p>SOURCE  Therapeutic Solutions International<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA40663&amp;Transmission_Id=202104130900PR_NEWS_USPR_____LA40663&amp;DateId=20210413\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company Announces Second Therapeutic Candidate for Leveraging Regenerative and Immunological Approaches for Overcoming &gt; $78.5 Billion Dollar Addiction Epidemic PR Newswire ELK CITY, Idaho, April 13, 2021 \/PRNewswire\/ &#8212;\u00a0Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced filing of a patent with new data covering a cord blood based intranasal product demonstrated to reduce adverse mental effects associated with opioid addiction.\u00a0 In the series of studies, inflammation was stimulated in the brains of animals using inducers and activators of TLR4, a protein associated with opioid addiction.\u00a0 Administration of the Company&#8217;s cord blood based therapeutic resulted in suppression of TLR4 as well as inhibition of inflammation in the brain. &#8220;In recent times numerous publications have reported the link between brain inflammation and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-475613","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company Announces Second Therapeutic Candidate for Leveraging Regenerative and Immunological Approaches for Overcoming &gt; $78.5 Billion Dollar Addiction Epidemic PR Newswire ELK CITY, Idaho, April 13, 2021 \/PRNewswire\/ &#8212;\u00a0Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced filing of a patent with new data covering a cord blood based intranasal product demonstrated to reduce adverse mental effects associated with opioid addiction.\u00a0 In the series of studies, inflammation was stimulated in the brains of animals using inducers and activators of TLR4, a protein associated with opioid addiction.\u00a0 Administration of the Company&#8217;s cord blood based therapeutic resulted in suppression of TLR4 as well as inhibition of inflammation in the brain. &#8220;In recent times numerous publications have reported the link between brain inflammation and &hellip; Continue reading &quot;Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-13T13:04:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA40663&amp;sd=2021-04-13\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction\",\"datePublished\":\"2021-04-13T13:04:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/\"},\"wordCount\":397,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA40663&amp;sd=2021-04-13\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/\",\"name\":\"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA40663&amp;sd=2021-04-13\",\"datePublished\":\"2021-04-13T13:04:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA40663&amp;sd=2021-04-13\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA40663&amp;sd=2021-04-13\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/","og_locale":"en_US","og_type":"article","og_title":"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction - Market Newsdesk","og_description":"Company Announces Second Therapeutic Candidate for Leveraging Regenerative and Immunological Approaches for Overcoming &gt; $78.5 Billion Dollar Addiction Epidemic PR Newswire ELK CITY, Idaho, April 13, 2021 \/PRNewswire\/ &#8212;\u00a0Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced filing of a patent with new data covering a cord blood based intranasal product demonstrated to reduce adverse mental effects associated with opioid addiction.\u00a0 In the series of studies, inflammation was stimulated in the brains of animals using inducers and activators of TLR4, a protein associated with opioid addiction.\u00a0 Administration of the Company&#8217;s cord blood based therapeutic resulted in suppression of TLR4 as well as inhibition of inflammation in the brain. &#8220;In recent times numerous publications have reported the link between brain inflammation and &hellip; Continue reading \"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-13T13:04:05+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA40663&amp;sd=2021-04-13","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction","datePublished":"2021-04-13T13:04:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/"},"wordCount":397,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA40663&amp;sd=2021-04-13","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/","name":"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA40663&amp;sd=2021-04-13","datePublished":"2021-04-13T13:04:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA40663&amp;sd=2021-04-13","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA40663&amp;sd=2021-04-13"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/475613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=475613"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/475613\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=475613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=475613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=475613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}